# Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

> **NCT06545942** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **MOMA Therapeutics** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor
- Prostate Cancer
- Pancreas Cancer
- Breast Cancer
- Ovarian Cancer
- Homologous Recombination Deficiency

## Interventions

- **DRUG:** MOMA-313
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT06545942
- **Lead sponsor:** MOMA Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-11-30
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06545942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06545942, "Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06545942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*